News
CELLO Study to Explore Early Treatment of Multiple Sclerosis
Yale University announced today the initiation of a multicenter study aimed at treating early stage multiple sclerosis (MS). Supported by and in collaboration with Genentech, a member of the Roche Group, the study, known as “CELLO,” will investigate whether short-term treatment with ocrelizumab in patients with MRI lesions consistent with early MS without clinical disease—known as radiologic isolated syndrome—prevents the onset of symptoms.